secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lipocine Inc. (LPCN)
CIK:        0001535955
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001493152-26-001254
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lipocine: Phase 3 PPD trial passes second DSMB safety review; topline data due Q2 2026
--------------------------------------------------------------------------------

- DSMB reviewed safety data from 82 randomized patients; recommended trial continue without modification.
- No drug discontinuations, excessive sedation, loss of consciousness, or drug-related SAEs reported.
- Study no longer screening new participants; still enrolling eligible patients.
- Topline safety and efficacy results expected early Q2 2026; data to support NDA submission.
- CEO cites confidence in safety profile; potential for new treatment paradigm.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1535955/000149315226001254/0001493152-26-001254-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1535955/000149315226001254/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-001254

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer